Literature DB >> 9736215

Platelet proteins as autoantibody targets in idiopathic thrombocytopenic purpura.

H Wadenvik1, D Stockelberg, M Hou.   

Abstract

Idiopathic thrombocytopenic purpura (ITP), caused by autoantibodies directed against certain platelet antigens, is the most common entity of the immune thrombocytopenias. ITP is an acquired disorder and can affect both children and adults. However, the clinical syndromes of ITP are distinct between children and adults. Childhood (acute) ITP characteristically is acute in onset, occurs within 1-2 weeks of an infection, usually of viral origin, resolves spontaneously within 6 months. Adult (chronic) ITP has an insidious onset and rarely resolves spontaneously. Over the last decade considerable new information has accumulated as to the pathophysiological mechanisms of immune thrombocytopenias. In addition, most of the knowledge on this disorder has been obtained from studies of adult patients with chronic ITP. The present work gives an updated overview of the platelet autoantigens and the molecular immunological reactions in ITP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736215     DOI: 10.1111/j.1651-2227.1998.tb01230.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  3 in total

1.  Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia.

Authors:  Mattias Olsson; Pierre Bruhns; William A Frazier; Jeffrey V Ravetch; Per-Arne Oldenborg
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

2.  Anti-platelet antibodies associated with the Canale-Smith syndrome bind to the same platelet glycoprotein complexes as those of idiopathic thrombocytopenic purpura patients.

Authors:  T Grodzicky; J B Bussel; K B Elkon
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Infantile Immune Thrombocytopenic Purpura Secondary to Perinatal Transfer of SARS-CoV-2 Antibody.

Authors:  Jitendra Oswal; Bhakti Sarangi; Karthik Badarayan
Journal:  Indian Pediatr       Date:  2022-02-15       Impact factor: 1.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.